Literature DB >> 32674070

The natural history and treatment of non-functioning pituitary adenomas (non-functioning PitNETs).

Maria P Yavropoulou1, Marina Tsoli1, Konstantinos Barkas2, Gregory Kaltsas1, Ashley Grossman3,4.   

Abstract

Non-functioning pituitary adenomas, recently alternatively termed pituitary neuroendocrine tumours (NFpitNETs), are mostly benign neoplasms that are not associated with a hormonal hypersecretory syndrome. The clinical spectrum of NFpitNETs varies from completely asymptomatic to the development of panhypopituitarism and manifestations attributed to mass effects on nearby structures. NFpitNETs follow generally an indolent course, but in 5-10% of cases they exhibit more aggressive behaviour, characterised by rapid growth, invasiveness and early recurrence. The initial size of the adenoma, the presence of symptoms and the histological subtype are related to the natural course of NFpitNETs. Active surveillance is usually the strategy of choice in the case of an asymptomatic NFpitNET, while surgical resection is recommended in case of visual and/or neurological abnormalities or rapid tumour growth. Based on previous and emerging data, approximately 50% of patients show tumour growth, while 20% of patients with NF-macroadenomas on active surveillance may require further intervention during a follow-up period of 7 years. Adjuvant radiotherapy is usually considered for large residual tumours or recurrent and/or aggressive adenomas, but there is evidence that medical therapy, especially with cabergoline, can occasionally be beneficial, whereas newer molecular agents are under investigation. Thus, while highly effective medical therapy is awaited, a move towards a more conservative approach seems appropriate, at least until we have better molecular markers of progressiveness.

Entities:  

Keywords:  management; mortality; natural history; non-functioning pituitary adenomas; prognosis; surgery; temozolomide; tyrosine kinase inhibitors

Year:  2020        PMID: 32674070     DOI: 10.1530/ERC-20-0136

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

Review 1.  Dopamine Agonists in the Management of Non-Functioning Pituitary Adenomas.

Authors:  C Capatina; C Poiana
Journal:  Acta Endocrinol (Buchar)       Date:  2021 Jul-Sep       Impact factor: 0.877

2.  Educational Case: Pituitary Adenoma.

Authors:  Ayda Javanbakht; George Zanazzi
Journal:  Acad Pathol       Date:  2021-08-11

Review 3.  Immune Checkpoints: Therapeutic Targets for Pituitary Tumors.

Authors:  Ding Nie; Yimeng Xue; Qiuyue Fang; Jianhua Cheng; Bin Li; Dawei Wang; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  Dis Markers       Date:  2021-08-16       Impact factor: 3.434

4.  Posterior pituitary tumours: patient outcomes and determinants of disease recurrence or persistence.

Authors:  Liza Das; Kim Vaiphei; Ashutosh Rai; Chirag Kamal Ahuja; Paramjeet Singh; Ishani Mohapatra; Rajesh Chhabra; Anil Bhansali; Bishan Dass Radotra; Ashley B Grossman; Márta Korbonits; Pinaki Dutta
Journal:  Endocr Connect       Date:  2021-04       Impact factor: 3.335

5.  Prediction of the Recurrence of Non-Functioning Pituitary Adenomas Using Preoperative Supra-Intra Sellar Volume and Tumor-Carotid Distance.

Authors:  Wenli Chen; Mengqi Wang; Chengbin Duan; Shun Yao; Haosen Jiao; Zongming Wang; Bin Hu; Zhigang Mao; Yonghong Zhu; Haijun Wang
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-30       Impact factor: 5.555

6.  Staged endovascular treatment of a coexisting parasellar aneurysm and endoscopic resection of a pituitary macroadenoma: illustrative case.

Authors:  Aishwarya Nene; Christopher S Hong; Declan McGuone; Charles C Matouk; S Bulent Omay
Journal:  J Neurosurg Case Lessons       Date:  2022-03-07

7.  Phosphorylated EGFR (pEGFR T693) as a Novel Predictor of Recurrence in Non-Functioning Pituitary Adenomas.

Authors:  Ashutosh Rai; Liza Das; Kanchan K Mukherjee; Sivashanmugam Dhandapani; Manjul Tripathi; Chirag Kamal Ahuja; Bishan Dass Radotra; Pinaki Dutta
Journal:  Front Endocrinol (Lausanne)       Date:  2021-07-05       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.